Form 6-K VERMILION ENERGY INC. For: Oct 28

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the month of October 2016

 

Commission File Number: 001-35829

 

Vermilion Energy Inc. 

(Exact name of registrant as specified in its charter)

 

 

3500, 520 – 3^rd Avenue S.W., Calgary, Alberta T2P 0R3

 (Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☐

Form 40-F ☒

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1).        

 

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

 

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes ☐

No ☒

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-               .

 

 

 

 

 

Exhibit		Description
99.1		News Release dated October 28, 2016 - Cardiome to Hold Third Quarter 2016 Financial Results Conference Call on November 7

 

 

 

By:		/s/ Curtis W. Hicks
Title:		Curtis W. Hicks, Executive VP and Chief Financial Officer

 Date: October 28, 2016

Exhibit 99.1

 

Cardiome to Hold Third Quarter 2016 Financial Results Conference Call on November 7

NASDAQ: CRME    TSX: COM

VANCOUVER, Oct. 28, 2016 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it will report financial results for the third quarter ended September 30, 2016 on Friday, November 4, 2016. Cardiome will hold a conference call and webcast at 4:00 p.m. Eastern (1:00 p.m. Pacific) on Monday, November 7, 2016 to discuss the results.

To access the conference call, please dial 416-764-8688 or 888-390-0546 and use conference ID 18697541. The webcast can be accessed through the following link:

http://event.on24.com/r.htm?e=1288274&s=1&k=E8DD5BE99805E25D75325B53EC401D83

Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through December 7, 2016. Please dial 416-764-8677 or 888-390-0541 and enter code 697541 # to access the replay.

About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a specialty pharmaceutical company dedicated to the development and commercialization of innovative therapies that will improve the quality of life and health of patients suffering from disease. Cardiome has two marketed, in-hospital, cardiology products, BRINAVESS^® (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, and AGGRASTAT^® (tirofiban HCl) a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD^® and ESMOCARD LYO^® (esmolol hydrochloride), a short-acting beta-blocker used to control rapid heart rate in a number of cardiovascular indications, on behalf of their partner AOP Orphan Pharma in select European markets. Cardiome has also licensed: XYDALBA™ (dalbavancin hydrochloride), a second generation, semi-synthetic lipoglycopeptide approved in the EU for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults for select European and Middle Eastern nations and Canada from Allergan; and TREVYENT^®, a development stage drug device combination that is under development for Pulmonary Arterial Hypertension for Europe, the Middle East and for Canadian markets from SteadyMed Therapeutics.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.

SOURCE Cardiome Pharma Corp.

%CIK: 0001036141

For further information: David Dean, VP Business Development and Investor Relations, (604) 677-6905 ext. 311 or Toll Free: 1-800-330-9928, [email protected]

CO: Cardiome Pharma Corp.

CNW 08:00e 28-OCT-16

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Vermilion Energy (VET:CN) (VET) PT Raised to Cdn$22 at National Bank Financial
• It’s Draft Day: Damar Hamlin Helps Build the Abbott HeartMates Team
• Vermilion Energy (VET:CN) (VET) PT Raised to Cdn$20.50 at Canaccord Genuity